What will 2024 be remembered for?
We have collected some striking figures and facts about the achievements of the Rus Biopharm group of companies, of which PSK Pharma is an important part, in order to summarize the results of the outgoing year.
In 2024, the portfolio of medicines was significantly expanded, with more than 15 products developed and registered in Russia. Among them:
• drugs for patients with type 2 diabetes and/or obesity – Sugales, Wesfol, Insudive, Vildagliptin PSK
• the first domestic double bronchodilator Respihale
• the only infusion antibiotic with the active ingredient tedizolid
• a drug for the treatment of orphan diseases – Gaucher's disease and Niemann-Pick disease
• new drugs and dosages of existing medicines for HIV patients
More than 4.8 million packages of drugs were produced by our factory.
«Rus Biopharm», the Ministry of Investment, Industry and Science of the Moscow Region and the «Dubna» SEZ signed a cooperation agreement to implement an investment project for the production of active pharmaceutical substances in the Moscow Region, with investments in the project amounting to at least 1.5 billion rubles.
PSK Pharma has once again been included in the ranking of the best employers in the country according to hh.ru and RBC
An innovative method for obtaining Ritonavir has been patented
A modern social information resource, Breathe Easy, has been launched for patients with asthma and COPD, as well as their loved ones, in cooperation with the Russian Respiratory Society.
Next year, we will continue to talk about the results of our large–scale work - the expansion of the research and production infrastructure, the research carried out, as well as the contribution our team has made to providing patients with modern and high-quality medicines.
«PSK Pharma» – we have something to be proud of!